Biotoxtech Co., Ltd. (KOSDAQ:086040)
South Korea · Delayed Price · Currency is KRW 2,445.00
+50.00 (2.09%)
At close: Jun 18, 2026
Biotoxtech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 47,636 | 47,017 | 41,341 | 32,631 | 37,292 | 32,717 |
Other Revenue | -0 | -0 | -0 | - | - | - |
| 47,636 | 47,017 | 41,341 | 32,631 | 37,292 | 32,717 | |
Revenue Growth (YoY) | 9.26% | 13.73% | 26.69% | -12.50% | 13.98% | 23.79% |
Cost of Revenue | 42,062 | 41,215 | 38,842 | 30,769 | 24,863 | 22,208 |
Gross Profit | 5,574 | 5,802 | 2,499 | 1,862 | 12,429 | 10,509 |
Selling, General & Admin | 8,932 | 8,765 | 8,810 | 8,773 | 9,319 | 5,362 |
Research & Development | 666.99 | 642.58 | 694.43 | 453.68 | - | - |
Amortization of Goodwill & Intangibles | 85.06 | 83.12 | 42.21 | 37.64 | 37.34 | 30.24 |
Other Operating Expenses | 167.31 | 165.66 | 195.81 | 258.63 | 155.54 | 125.31 |
Operating Expenses | 11,884 | 11,710 | 11,118 | 10,538 | 11,629 | 5,878 |
Operating Income | -6,310 | -5,908 | -8,619 | -8,676 | 800.05 | 4,632 |
Interest Expense | -5,499 | -5,425 | -5,086 | -3,764 | -2,015 | -832.82 |
Interest & Investment Income | 857.62 | 909.98 | 1,690 | 1,053 | 612.44 | 141.09 |
Earnings From Equity Investments | -3.46 | -4.11 | -42.5 | -3.53 | 175.8 | 204.81 |
Currency Exchange Gain (Loss) | 105.39 | -134.24 | 164.72 | -9 | -78.54 | -53.03 |
Other Non Operating Income (Expenses) | 2,142 | 2,191 | 3,933 | -442.15 | -1,531 | 756.47 |
EBT Excluding Unusual Items | -8,707 | -8,371 | -7,961 | -11,842 | -2,036 | 4,848 |
Gain (Loss) on Sale of Investments | 7,821 | 8,030 | -1,242 | 12.64 | 1,472 | 1,846 |
Gain (Loss) on Sale of Assets | -0.49 | -5.43 | -22.86 | -3.75 | -79.8 | -209.58 |
Other Unusual Items | - | - | 404.11 | - | - | - |
Pretax Income | -887.3 | -345.7 | -8,822 | -11,833 | -643.87 | 6,485 |
Income Tax Expense | 1,338 | 1,228 | 3,836 | -2,883 | -708.61 | -213.18 |
Earnings From Continuing Operations | -2,226 | -1,573 | -12,657 | -8,950 | 64.74 | 6,698 |
Earnings From Discontinued Operations | - | - | - | - | 1,447 | 281.99 |
Net Income to Company | -2,226 | -1,573 | -12,657 | -8,950 | 1,512 | 6,980 |
Minority Interest in Earnings | 2,995 | 2,736 | 6,230 | 4,073 | 1,214 | 134.31 |
Net Income | 769.13 | 1,163 | -6,427 | -4,878 | 2,725 | 7,114 |
Net Income to Common | 769.13 | 1,163 | -6,427 | -4,878 | 2,725 | 7,114 |
Net Income Growth | - | - | - | - | -61.69% | 172.19% |
Shares Outstanding (Basic) | 16 | 16 | 16 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 15 | 15 | 15 |
Shares Change (YoY) | -1.73% | -1.56% | 2.86% | 5.42% | -4.91% | 5.41% |
EPS (Basic) | 49.48 | 74.43 | -405.00 | -316.14 | 186.19 | 486.65 |
EPS (Diluted) | 49.48 | 74.43 | -405.00 | -316.14 | 185.86 | 444.28 |
EPS Growth | - | - | - | - | -58.17% | 148.20% |
Free Cash Flow | 3,567 | 4,515 | -9,097 | -20,691 | -31,985 | -3,273 |
Free Cash Flow Per Share | 229.45 | 289.02 | -573.25 | -1341.02 | -2185.30 | -212.62 |
Gross Margin | 11.70% | 12.34% | 6.04% | 5.71% | 33.33% | 32.12% |
Operating Margin | -13.25% | -12.57% | -20.85% | -26.59% | 2.15% | 14.16% |
Profit Margin | 1.62% | 2.47% | -15.55% | -14.95% | 7.31% | 21.74% |
Free Cash Flow Margin | 7.49% | 9.60% | -22.00% | -63.41% | -85.77% | -10.00% |
EBITDA | -1,924 | -1,576 | -4,521 | -4,998 | 2,745 | 6,304 |
EBITDA Margin | -4.04% | -3.35% | -10.94% | -15.32% | 7.36% | 19.27% |
D&A For EBITDA | 4,386 | 4,333 | 4,098 | 3,679 | 1,945 | 1,672 |
EBIT | -6,310 | -5,908 | -8,619 | -8,676 | 800.05 | 4,632 |
EBIT Margin | -13.25% | -12.57% | -20.85% | -26.59% | 2.15% | 14.16% |
Advertising Expenses | - | 133.08 | 121.57 | 137.07 | 71.96 | 58.04 |